aluates Reports

$ 0.0

Automative

Onychomycosis (Tinea Unguium) Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: April 2024

Report Code: QYRE-Auto-34F2242

Global Onychomycosis Tinea Unguium Drug Market Insights and Forecast to 2027

BUY CHAPTERS

Onychomycosis (Tinea Unguium) Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-34F2242

Report

April 2024

Pages:123

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novartis

Pfizer Inc

Valeant Pharma

Xiuzheng Pharmaceutical

Qilu Pharmaceutical

Yangtze River

Torrent Pharma

J & J

Chengdu Brilliant

Hubei Hengan

Taro

Perrigo

Galderma pharm

Zhejiang Deyer

Moberg

Onychomycosis (Tinea Unguium) Drug - Market Size

The global market for Onychomycosis (Tinea Unguium) Drug was estimated to be worth US$ 3288 million in 2023 and is forecast to a readjusted size of US$ 4901.7 million by 2030 with a CAGR of 5.8% during the forecast period 2024-2030

Onychomycosis (Tinea Unguium) Drug - Market

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.

Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.

Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.

North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.

In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Onychomycosis (Tinea Unguium) Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Onychomycosis (Tinea Unguium) Drug by region & country, by Type, and by Application.

The Onychomycosis (Tinea Unguium) Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Onychomycosis (Tinea Unguium) Drug.

Market Segmentation

Scope of Onychomycosis (Tinea Unguium) Drug - Market Report

Report Metric	Details
Report Name	Onychomycosis (Tinea Unguium) Drug - Market
Forecasted market size in 2030	US$ 4901.7 million
CAGR	5.8%
Forecasted years	2024 - 2030
Segment by Type:	Oral Medication External Medicine
Segment by Application	Age under 18 Age 18-50 Age above 50
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Yangtze River, Torrent Pharma, J&J, Chengdu Brilliant, Novartis, Qilu Pharmaceutical, Xiuzheng Pharmaceutical, Hubei Hengan, TARO, Perrigo, Galderma pharm, Zhejiang Deyer, Valeant Pharma, Moberg
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Onychomycosis (Tinea Unguium) Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Onychomycosis (Tinea Unguium) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Onychomycosis (Tinea Unguium) Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Onychomycosis (Tinea Unguium) Drug - Market size in 2030?

Ans: The Onychomycosis (Tinea Unguium) Drug - Market size in 2030 will be US$ 4901.7 million.

What is the market share of major companies in Onychomycosis (Tinea Unguium) Drug - Market?

Ans: Global top five manufacturers hold a share about 35%.

What is the Onychomycosis (Tinea Unguium) Drug - Market share by type?

Ans: In terms of product, Oral Medication is the largest segment, with a share over 70%.

Who are the main players in the Onychomycosis (Tinea Unguium) Drug - Market report?

Ans: The main players in the Onychomycosis (Tinea Unguium) Drug - Market are Pfizer, Yangtze River, Torrent Pharma, J&J, Chengdu Brilliant, Novartis, Qilu Pharmaceutical, Xiuzheng Pharmaceutical, Hubei Hengan, TARO, Perrigo, Galderma pharm, Zhejiang Deyer, Valeant Pharma, Moberg

What are the Application segmentation covered in the Onychomycosis (Tinea Unguium) Drug - Market report?

Ans: The Applications covered in the Onychomycosis (Tinea Unguium) Drug - Market report are Age under 18, Age 18-50, Age above 50

What are the Type segmentation covered in the Onychomycosis (Tinea Unguium) Drug - Market report?

Ans: The Types covered in the Onychomycosis (Tinea Unguium) Drug - Market report are Oral Medication, External Medicine

1 Market Overview

1.1 Onychomycosis (Tinea Unguium) Drug Product Introduction

1.2 Global Onychomycosis (Tinea Unguium) Drug Market Size Forecast

1.3 Onychomycosis (Tinea Unguium) Drug Market Trends & Drivers

1.3.1 Onychomycosis (Tinea Unguium) Drug Industry Trends

1.3.2 Onychomycosis (Tinea Unguium) Drug Market Drivers & Opportunity

1.3.3 Onychomycosis (Tinea Unguium) Drug Market Challenges

1.3.4 Onychomycosis (Tinea Unguium) Drug Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Onychomycosis (Tinea Unguium) Drug Players Revenue Ranking (2023)

2.2 Global Onychomycosis (Tinea Unguium) Drug Revenue by Company (2019-2024)

2.3 Key Companies Onychomycosis (Tinea Unguium) Drug Manufacturing Base Distribution and Headquarters

2.4 Key Companies Onychomycosis (Tinea Unguium) Drug Product Offered

2.5 Key Companies Time to Begin Mass Production of Onychomycosis (Tinea Unguium) Drug

2.6 Onychomycosis (Tinea Unguium) Drug Market Competitive Analysis

2.6.1 Onychomycosis (Tinea Unguium) Drug Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Onychomycosis (Tinea Unguium) Drug Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Onychomycosis (Tinea Unguium) Drug as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Oral Medication

3.1.2 External Medicine

3.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type

3.2.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value, by Type (2019-2030)

3.2.3 Global Onychomycosis (Tinea Unguium) Drug Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Age under 18

4.1.2 Age 18-50

4.1.3 Age above 50

4.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application

4.2.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value, by Application (2019-2030)

4.2.3 Global Onychomycosis (Tinea Unguium) Drug Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region

5.1.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2019-2024)

5.1.3 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2025-2030)

5.1.4 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

5.2.2 North America Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

5.3.2 Europe Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

5.4.2 Asia Pacific Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

5.5.2 South America Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

5.6.2 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Onychomycosis (Tinea Unguium) Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Onychomycosis (Tinea Unguium) Drug Sales Value

6.3 United States

6.3.1 United States Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

6.3.2 United States Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Onychomycosis (Tinea Unguium) Drug Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

6.4.2 Europe Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Onychomycosis (Tinea Unguium) Drug Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

6.5.2 China Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

6.5.3 China Onychomycosis (Tinea Unguium) Drug Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

6.6.2 Japan Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Onychomycosis (Tinea Unguium) Drug Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

6.7.2 South Korea Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Onychomycosis (Tinea Unguium) Drug Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

6.8.2 Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Onychomycosis (Tinea Unguium) Drug Sales Value, 2019-2030

6.9.2 India Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

6.9.3 India Onychomycosis (Tinea Unguium) Drug Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Pfizer

7.1.1 Pfizer Profile

7.1.2 Pfizer Main Business

7.1.3 Pfizer Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.1.4 Pfizer Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.1.5 Pfizer Recent Developments

7.2 Yangtze River

7.2.1 Yangtze River Profile

7.2.2 Yangtze River Main Business

7.2.3 Yangtze River Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.2.4 Yangtze River Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.2.5 Yangtze River Recent Developments

7.3 Torrent Pharma

7.3.1 Torrent Pharma Profile

7.3.2 Torrent Pharma Main Business

7.3.3 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.3.4 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.3.5 J&J Recent Developments

7.4 J&J

7.4.1 J&J Profile

7.4.2 J&J Main Business

7.4.3 J&J Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.4.4 J&J Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.4.5 J&J Recent Developments

7.5 Chengdu Brilliant

7.5.1 Chengdu Brilliant Profile

7.5.2 Chengdu Brilliant Main Business

7.5.3 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.5.4 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.5.5 Chengdu Brilliant Recent Developments

7.6 Novartis

7.6.1 Novartis Profile

7.6.2 Novartis Main Business

7.6.3 Novartis Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.6.4 Novartis Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.6.5 Novartis Recent Developments

7.7 Qilu Pharmaceutical

7.7.1 Qilu Pharmaceutical Profile

7.7.2 Qilu Pharmaceutical Main Business

7.7.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.7.4 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.7.5 Qilu Pharmaceutical Recent Developments

7.8 Xiuzheng Pharmaceutical

7.8.1 Xiuzheng Pharmaceutical Profile

7.8.2 Xiuzheng Pharmaceutical Main Business

7.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.8.4 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.8.5 Xiuzheng Pharmaceutical Recent Developments

7.9 Hubei Hengan

7.9.1 Hubei Hengan Profile

7.9.2 Hubei Hengan Main Business

7.9.3 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.9.4 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.9.5 Hubei Hengan Recent Developments

7.10 TARO

7.10.1 TARO Profile

7.10.2 TARO Main Business

7.10.3 TARO Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.10.4 TARO Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.10.5 TARO Recent Developments

7.11 Perrigo

7.11.1 Perrigo Profile

7.11.2 Perrigo Main Business

7.11.3 Perrigo Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.11.4 Perrigo Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.11.5 Perrigo Recent Developments

7.12 Galderma pharm

7.12.1 Galderma pharm Profile

7.12.2 Galderma pharm Main Business

7.12.3 Galderma pharm Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.12.4 Galderma pharm Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.12.5 Galderma pharm Recent Developments

7.13 Zhejiang Deyer

7.13.1 Zhejiang Deyer Profile

7.13.2 Zhejiang Deyer Main Business

7.13.3 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.13.4 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.13.5 Zhejiang Deyer Recent Developments

7.14 Valeant Pharma

7.14.1 Valeant Pharma Profile

7.14.2 Valeant Pharma Main Business

7.14.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.14.4 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.14.5 Valeant Pharma Recent Developments

7.15 Moberg

7.15.1 Moberg Profile

7.15.2 Moberg Main Business

7.15.3 Moberg Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

7.15.4 Moberg Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) & (2019-2024)

7.15.5 Moberg Recent Developments

8 Industry Chain Analysis

8.1 Onychomycosis (Tinea Unguium) Drug Industrial Chain

8.2 Onychomycosis (Tinea Unguium) Drug Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Onychomycosis (Tinea Unguium) Drug Sales Model

8.5.2 Sales Channel

8.5.3 Onychomycosis (Tinea Unguium) Drug Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Novartis

Pfizer Inc

Valeant Pharma

Xiuzheng Pharmaceutical

Qilu Pharmaceutical

Yangtze River

Torrent Pharma

J & J

Chengdu Brilliant

Hubei Hengan

Taro

Perrigo

Galderma pharm

Zhejiang Deyer

Moberg

List of Tables

Table 1. Onychomycosis (Tinea Unguium) Drug Market Trends

Table 2. Onychomycosis (Tinea Unguium) Drug Market Drivers & Opportunity

Table 3. Onychomycosis (Tinea Unguium) Drug Market Challenges

Table 4. Onychomycosis (Tinea Unguium) Drug Market Restraints

Table 5. Global Onychomycosis (Tinea Unguium) Drug Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Onychomycosis (Tinea Unguium) Drug Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Onychomycosis (Tinea Unguium) Drug Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Onychomycosis (Tinea Unguium) Drug Product Type

Table 9. Key Companies Time to Begin Mass Production of Onychomycosis (Tinea Unguium) Drug

Table 10. Global Onychomycosis (Tinea Unguium) Drug Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Onychomycosis (Tinea Unguium) Drug as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Onychomycosis (Tinea Unguium) Drug Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Onychomycosis (Tinea Unguium) Drug Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Onychomycosis (Tinea Unguium) Drug Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Onychomycosis (Tinea Unguium) Drug Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2019-2024) & (%)

Table 27. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Onychomycosis (Tinea Unguium) Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Onychomycosis (Tinea Unguium) Drug Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Onychomycosis (Tinea Unguium) Drug Sales Value, (2025-2030) & (US$ Million)

Table 31. Pfizer Basic Information List

Table 32. Pfizer Description and Business Overview

Table 33. Pfizer Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 34. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Pfizer (2019-2024)

Table 35. Pfizer Recent Developments

Table 36. Yangtze River Basic Information List

Table 37. Yangtze River Description and Business Overview

Table 38. Yangtze River Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 39. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Yangtze River (2019-2024)

Table 40. Yangtze River Recent Developments

Table 41. Torrent Pharma Basic Information List

Table 42. Torrent Pharma Description and Business Overview

Table 43. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 44. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Torrent Pharma (2019-2024)

Table 45. Torrent Pharma Recent Developments

Table 46. J&J Basic Information List

Table 47. J&J Description and Business Overview

Table 48. J&J Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 49. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of J&J (2019-2024)

Table 50. J&J Recent Developments

Table 51. Chengdu Brilliant Basic Information List

Table 52. Chengdu Brilliant Description and Business Overview

Table 53. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 54. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Chengdu Brilliant (2019-2024)

Table 55. Chengdu Brilliant Recent Developments

Table 56. Novartis Basic Information List

Table 57. Novartis Description and Business Overview

Table 58. Novartis Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 59. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Novartis (2019-2024)

Table 60. Novartis Recent Developments

Table 61. Qilu Pharmaceutical Basic Information List

Table 62. Qilu Pharmaceutical Description and Business Overview

Table 63. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 64. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Qilu Pharmaceutical (2019-2024)

Table 65. Qilu Pharmaceutical Recent Developments

Table 66. Xiuzheng Pharmaceutical Basic Information List

Table 67. Xiuzheng Pharmaceutical Description and Business Overview

Table 68. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 69. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Xiuzheng Pharmaceutical (2019-2024)

Table 70. Xiuzheng Pharmaceutical Recent Developments

Table 71. Hubei Hengan Basic Information List

Table 72. Hubei Hengan Description and Business Overview

Table 73. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 74. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Hubei Hengan (2019-2024)

Table 75. Hubei Hengan Recent Developments

Table 76. TARO Basic Information List

Table 77. TARO Description and Business Overview

Table 78. TARO Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 79. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of TARO (2019-2024)

Table 80. TARO Recent Developments

Table 81. Perrigo Basic Information List

Table 82. Perrigo Description and Business Overview

Table 83. Perrigo Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 84. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Perrigo (2019-2024)

Table 85. Perrigo Recent Developments

Table 86. Galderma pharm Basic Information List

Table 87. Galderma pharm Description and Business Overview

Table 88. Galderma pharm Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 89. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Galderma pharm (2019-2024)

Table 90. Galderma pharm Recent Developments

Table 91. Zhejiang Deyer Basic Information List

Table 92. Zhejiang Deyer Description and Business Overview

Table 93. Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 94. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Zhejiang Deyer (2019-2024)

Table 95. Zhejiang Deyer Recent Developments

Table 96. Valeant Pharma Basic Information List

Table 97. Valeant Pharma Description and Business Overview

Table 98. Valeant Pharma Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 99. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Valeant Pharma (2019-2024)

Table 100. Valeant Pharma Recent Developments

Table 101. Moberg Basic Information List

Table 102. Moberg Description and Business Overview

Table 103. Moberg Onychomycosis (Tinea Unguium) Drug Products, Services and Solutions

Table 104. Revenue (US$ Million) in Onychomycosis (Tinea Unguium) Drug Business of Moberg (2019-2024)

Table 105. Moberg Recent Developments

Table 106. Key Raw Materials Lists

Table 107. Raw Materials Key Suppliers Lists

Table 108. Onychomycosis (Tinea Unguium) Drug Downstream Customers

Table 109. Onychomycosis (Tinea Unguium) Drug Distributors List

Table 110. Research Programs/Design for This Report

Table 111. Key Data Information from Secondary Sources

Table 112. Key Data Information from Primary Sources

Table 113. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Onychomycosis (Tinea Unguium) Drug Product Picture

Figure 2. Global Onychomycosis (Tinea Unguium) Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Onychomycosis (Tinea Unguium) Drug Sales Value (2019-2030) & (US$ Million)

Figure 4. Onychomycosis (Tinea Unguium) Drug Report Years Considered

Figure 5. Global Onychomycosis (Tinea Unguium) Drug Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Onychomycosis (Tinea Unguium) Drug Revenue in 2023

Figure 7. Onychomycosis (Tinea Unguium) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Oral Medication Picture

Figure 9. External Medicine Picture

Figure 10. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Onychomycosis (Tinea Unguium) Drug Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Age under 18

Figure 13. Product Picture of Age 18-50

Figure 14. Product Picture of Age above 50

Figure 15. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Onychomycosis (Tinea Unguium) Drug Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Onychomycosis (Tinea Unguium) Drug Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Onychomycosis (Tinea Unguium) Drug Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Onychomycosis (Tinea Unguium) Drug Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Onychomycosis (Tinea Unguium) Drug Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Onychomycosis (Tinea Unguium) Drug Sales Value (%), (2019-2030)

Figure 28. United States Onychomycosis (Tinea Unguium) Drug Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Onychomycosis (Tinea Unguium) Drug Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Onychomycosis (Tinea Unguium) Drug Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Onychomycosis (Tinea Unguium) Drug Sales Value by Application (%), 2023 VS 2030

Figure 34. China Onychomycosis (Tinea Unguium) Drug Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

Figure 36. China Onychomycosis (Tinea Unguium) Drug Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Onychomycosis (Tinea Unguium) Drug Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Onychomycosis (Tinea Unguium) Drug Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Onychomycosis (Tinea Unguium) Drug Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Onychomycosis (Tinea Unguium) Drug Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value by Application (%), 2023 VS 2030

Figure 46. India Onychomycosis (Tinea Unguium) Drug Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Onychomycosis (Tinea Unguium) Drug Sales Value by Type (%), 2023 VS 2030

Figure 48. India Onychomycosis (Tinea Unguium) Drug Sales Value by Application (%), 2023 VS 2030

Figure 49. Onychomycosis (Tinea Unguium) Drug Industrial Chain

Figure 50. Onychomycosis (Tinea Unguium) Drug Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions